Bilobalide

Bilobalide is a sesquiterpene trilactone, a fifteen-carbon terpenoid distinguished by three lactone rings and an unusual tert-butyl group. It belongs to the small family of terpene trilactones found in Ginkgo biloba, alongside the structurally related ginkgolides, and it is thought to arise biosynthetically from a partially degraded ginkgolide skeleton ^[1]. Its compact, highly oxygenated and strained structure has made it a notable target for chemists; a concise laboratory synthesis of the molecule was reported only in 2019, a reflection of the difficulty of assembling its congested framework ^[3].

The compound occurs chiefly in the leaves of the ginkgo tree, one of the oldest surviving species of tree, with only trace amounts elsewhere in the plant ^[1]. In commerce it is encountered almost entirely as a component of standardized Ginkgo biloba leaf extracts, which are prepared to contain defined proportions of terpene trilactones (the ginkgolides and bilobalide) and flavonol glycosides ^[1]. Because these extracts are refined to fixed specifications, bilobalide is generally consumed as one of several active constituents rather than in isolated form ^[1].

Most scientific interest in bilobalide centers on the nervous system. In cell and tissue studies it has shown neuroprotective activity, reducing the injury that follows overactivation of nerve cells by glutamate and the damage caused by oxygen and glucose deprivation, a model of stroke-like ischemia ^[2]. One proposed contributor to this protection is its ability to curb the release of the neurotransmitter glycine under ischemic conditions, even though it does not appear to bind glycine receptors directly ^[2]. Researchers have also reported that it can rescue certain cognitive deficits in animal models, including mouse models of Down syndrome, which has sharpened interest in its central actions ^[3].

A recurring theme in this work is bilobalide's interaction with the GABA system. Laboratory studies have identified it as an antagonist, or negative modulator, of GABA-A receptors, the main inhibitory neurotransmitter receptors in the brain, an activity demonstrated through competitive inhibition of ligand binding and reduced chloride flux ^[4]. Curiously, blocking GABA-A receptors would usually be expected to promote seizures, yet bilobalide is not notably convulsant and is instead neuroprotective, which has led scientists to suspect that additional, still-unidentified targets are involved ^[3][4]. It has also been noted to induce certain liver enzymes, a property that may underlie some interactions reported with ginkgo supplements ^[1].

Bilobalide itself is not a licensed medicine and is not separately regulated in most places; it reaches consumers within herbal ginkgo products, which are marketed as dietary supplements or, in some countries, as traditional or phytopharmaceutical preparations ^[1]. Standardization of the terpene trilactone content, including bilobalide, is a routine part of quality control for these extracts ^[1]. Much of the evidence for its individual effects comes from laboratory and animal studies rather than from trials of the pure compound in humans ^[2][3].

As part of standardized ginkgo extracts it has a long history of reasonable tolerability. Isolated high-dose bilobalide has GABA-antagonist properties that in theory could lower seizure threshold, so caution is warranted. Ginkgo constituents can also affect bleeding, so people on blood thinners should be careful.